Virological markers of progression: a UK experience.
Loveday
C
C
University College London Medical School, UK.
D019380:Anti-HIV Agents / Q000627:therapeutic use; D015415:Biomarkers; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006678:HIV / Q000187:drug effects; D016655:HIV Core Protein p24 / Q000097:blood / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000821:virology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D015233:Models, Statistical; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood; D012194:RNA-Directed DNA Polymerase / Q000276:immunology; D015996:Survival Rate; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015415:Biomarkers; D016655:HIV Core Protein p24; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D012194:RNA-Directed DNA Polymerase